NeuroVive Pharmaceutical AB Interim report January – March 2018
Successful rights issue
Press releases
NeuroVive and Yungjin reports positive KL1333 phase I clinical study results paving the way for further clinical development
Lund, Sweden and Seoul, Korea, 21 May 2018 – NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) and Yungjin Pharm Corporation Ltd (South Korea Stock Market, KRX 003520) today jointly an ...
Amendment: Resolutions from Annual General Meeting in NeuroVive Pharmaceutical AB (publ)
Lund, Sweden, 27 April 2018 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) (“NeuroVive”) today on 27 April 2018 held its Annual General Meeting (AGM). A summary of the resolutions ...
Preferential rights issue in NeuroVive oversubscribed
THIS DOCUMENT IS NOT TO BE DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE US, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEELAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA OR IN ANY OTHER JURISDICTION W ...
NeuroVive publishes supplementary prospectus
THIS DOCUMENT IS NOT TO BE DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE US, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEELAND, SOUTH AFRICA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE THE DI ...
NeuroVive’s Board Members, Senior Executives and employees will subscribe units in the ongoing rights issue
In the current rights issue in NeuroVive, the Board, Senior Executives and employees have undertaken to subscribe for at least 191,200 units equivalent to MSEK 1.5. The subscription period in [&hellip ...
NeuroVive’s KL1333 receives FDA Orphan Drug Designation for treatment of mitochondrial diseases
Lund, Sweden, 18 April 2018 NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that it has been granted Orphan Drug Designation by t ...
NeuroVive publishes prospectus in connection with preferential rights issue
THIS DOCUMENT IS NOT TO BE DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE US, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEELAND, SOUTH AFRICA OR IN ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OF ...
NeuroVive Pharmaceutical AB publishes 2017 Annual report
Lund, Sweden, 26 March, 2018, NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the English version of the Annual report for 2017 is now available on the company's ...
Notice of Annual General Meeting of Shareholders in NeuroVive Pharmaceutical AB
The Board of Directors of NeuroVive Pharmaceutical AB (publ) has issued a notice to the Annual General Meeting, which is to take place on Friday, April 27, 2017, at 10 am at Medicon Village, Scheelevä ...
NeuroVive Pharmaceutical AB (publ): report from EGM
Today, 22 March 2018, an extraordinary general meeting was held in NeuroVive Pharmaceutical AB (publ) ("NeuroVive" or the "Company"). A summary of the resolutions follows. All resolutions were passed ...
NeuroVive Pharmaceutical AB Year End Report January – December 2017
Strong trend for mitochondrial disorder projects